# APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

> **NCT06687070** · PHASE1 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** APG -2449
- **DRUG:** PLD

## Key facts

- **NCT ID:** NCT06687070
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2026-05
- **Final completion:** 2027-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06687070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06687070, "APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06687070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*